BREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
RSV cases typically peak between late December and mid-February, but cases last yearAs of late April, the rate of RSV hospitalizations for the current season was around 51 per 100,000 people,GSK’s trial"It’s not like you have to wait to the very last minute because it’s not going to last long enough," Dormitzer said."We know from studies we have done that getting a vaccine — for example, in the fall — should cover you through the next RSV season.
So far, commonly reported side effects in the trial include injection site pain, fatigue and muscle pain. Dormitzer said it’s hard to know what to make of the Guillain-Barré case but added, “I would not say it’s a great concern at this point.” The FDA has asked Pfizer to conduct a study on the risk of Guillain-Barré after its vaccine is approved.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
RSV in First Year Could Raise Baby’s Risk of AsthmaChildren who didn’t contract RSV in their first year of life had a 26 percent lower risk of asthma later in life. Learn more about the connection here.
Weiterlesen »
US approves 1st vaccine for RSV after decades of attemptsThe U.S. has approved the first vaccine for RSV, shots to protect older adults
Weiterlesen »
US FDA declines to approve Ascendis' hormone disorder therapyAscendis Pharma A/S said on Monday the U.S. Food & Drug Administration had declined to approve the Danish drugmaker's experimental therapy to treat adult patients with a hormone disorder called hypoparathyroidism, citing concerns linked to manufacturing control of the drug and device combination.
Weiterlesen »